SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
BörsenkürzelSIBN
Name des UnternehmensSI-BONE Inc
IPO-datumOct 17, 2018
CEOMs. Laura A. Francis
Anzahl der mitarbeiter349
WertpapierartOrdinary Share
GeschäftsjahresendeOct 17
Addresse471 El Camino Real, Suite 101
StadtSANTA CLARA
BörseMoscow Interbank Currency Exchange (MICEX)
LandUnited States of America
Postleitzahl95050
Telefon14082070700
Websitehttps://si-bone.com/
BörsenkürzelSIBN
IPO-datumOct 17, 2018
CEOMs. Laura A. Francis
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten